Show items per page
Elements: 13
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA) Iannone, Florenzo; Courvoisier, Delphine S; Gottenberg, Jacques Eric; Hernandez, Maria Victoria; ... Finckh, Axel 2017
add to browser selection
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM) Mueller, Ruediger B; Reshiti, Nazim; Kaegi, Toni; Finckh, Axel; ... von Kempis, Johannes 2017
add to browser selection
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers Mercer, Louise K; Askling, Johan; Raaschou, Pauline; Dixon, William G; ... Listing, Joachim 2017
add to browser selection
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update EULAR 2017
add to browser selection
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis Walker, Ulrich A; Jaeger, Veronika K; Chatzidionysiou, Katerina; Hetland, Merete L; ... Gabay, Cem 2016
add to browser selection
Biological agents in monotherapy for the treatment of rheumatoid arthritis Gabay, Cem; Hasler, P; Kyburz, D; So, A; ... Walker, U 2014
add to browser selection
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration Chatzidionysiou, Katerina; Lie, Elisabeth; Nasonov, Evgeny; Lukina, Galina; ... Gabay, Cem 2012
add to browser selection
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients Martin-du-pan, Sophie Marie Catherine; Scherer, Almut; Gabay, Cem; Finckh, Axel 2012
add to browser selection
Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion Walker, Ulrich A; Courvoisier, Delphine; Dudler, Jean; Aeberli, Daniel; ... Finckh, Axel 2011
add to browser selection
Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis Salliot, Carine; Finckh, Axel; Katchamart, Wanruchada; Lu, Yan; ... Keystone, Edward 2011
add to browser selection
Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy Sommer, W H.; Ganiere, Vincent; Gachoud, D.; Keta, A.; ... Aujesky, D. 2008
add to browser selection
Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis Duffy, T N; Genta, Marcia; Moll, Solange; Martin, Pierre-Yves; Gabay, Cem 2006
add to browser selection
Proteasome inhibition: a new anti-inflammatory strategy Elliott, Peter J.; Zollner, Thomas Matthias; Boehncke, Wolf-Henning 2003